Next at #ASH25: #Leukemia expert @raajitrampal.bsky.social will present durable efficacy and long-term safety of pelabresib plus ruxolitinib in JAK inhibitor–naive #myelofibrosis from the phase 3 MANIFEST-2 study. @mskcancercenter.bsky.social @ash.hematology.org #leusm
Learn more: bit.ly/3MnLwee
Learn more: bit.ly/3MnLwee
December 8, 2025 at 6:45 PM
Next at #ASH25: #Leukemia expert @raajitrampal.bsky.social will present durable efficacy and long-term safety of pelabresib plus ruxolitinib in JAK inhibitor–naive #myelofibrosis from the phase 3 MANIFEST-2 study. @mskcancercenter.bsky.social @ash.hematology.org #leusm
Learn more: bit.ly/3MnLwee
Learn more: bit.ly/3MnLwee
The approved medication ruxolitinib dampens inflammatory responses to malaria and can enhance immune memory to the parasite in infected volunteers, supporting its potential as an adjunctive therapy to improve outcomes. #ScienceTranslationalMedicine https://scim.ag/44tu6TB
Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum
Adjunctive ruxolitinib reduces inflammatory response after experimental malaria challenge and enhances immune memory responses to reinfection.
scim.ag
December 1, 2025 at 5:05 PM
The approved medication ruxolitinib dampens inflammatory responses to malaria and can enhance immune memory to the parasite in infected volunteers, supporting its potential as an adjunctive therapy to improve outcomes. #ScienceTranslationalMedicine https://scim.ag/44tu6TB
#pharmasky #SkyRx Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in
Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
using Simulated Treatment Comparisons
jheor.org/api/v1/artic...
Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
using Simulated Treatment Comparisons
jheor.org/api/v1/artic...
December 19, 2024 at 6:02 AM
#pharmasky #SkyRx Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in
Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
using Simulated Treatment Comparisons
jheor.org/api/v1/artic...
Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
using Simulated Treatment Comparisons
jheor.org/api/v1/artic...
🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD!
🔊 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 buff.ly/LyxrSuu #SCD #SCDC
🔊 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 buff.ly/LyxrSuu #SCD #SCDC
September 30, 2025 at 5:05 PM
🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD!
🔊 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 buff.ly/LyxrSuu #SCD #SCDC
🔊 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 buff.ly/LyxrSuu #SCD #SCDC
New Blood Advances issue out now featuring:
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis buff.ly/BQ4F85h
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis buff.ly/BQ4F85h
August 26, 2025 at 6:03 PM
New Blood Advances issue out now featuring:
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis buff.ly/BQ4F85h
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis buff.ly/BQ4F85h
Open Access UCL Research: Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
January 12, 2026 at 5:02 PM
Open Access UCL Research: Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
discovery.ucl.ac.uk/id/eprint/10...
discovery.ucl.ac.uk/id/eprint/10...
Hemofagositik lenfohistiositoz (HLH), ölüm oranı %40'a varan nadir ve genellikle agresif bir hiperaktif inflamasyon sendromudur. Ruxolitinib adlı ilaç sonuçları yayınlanmış. Ee sonuç? 👇+
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
March 8, 2024 at 6:54 PM
Hemofagositik lenfohistiositoz (HLH), ölüm oranı %40'a varan nadir ve genellikle agresif bir hiperaktif inflamasyon sendromudur. Ruxolitinib adlı ilaç sonuçları yayınlanmış. Ee sonuç? 👇+
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Ruxolitinib delays nucleus pulposus cell senescence in rat intervertebral discs. Learn more in this recent JOR Spine article by Honggang Hao et al.: onlinelibrary.wiley....
April 25, 2025 at 4:17 PM
Ruxolitinib delays nucleus pulposus cell senescence in rat intervertebral discs. Learn more in this recent JOR Spine article by Honggang Hao et al.: onlinelibrary.wiley....
🎙️ Just published a new episode of Blood Podcast: Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT. Have a listen:
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
In this week's episode, we'll learn about stopping myeloma maintenance...
share.transistor.fm
May 15, 2025 at 4:20 PM
🎙️ Just published a new episode of Blood Podcast: Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT. Have a listen:
KU Leuven: nowy trop w leczeniu najgroźniejszych form malarii
Zespół badaczy z Instytutu Rega przy Katolickim Uniwersytecie w Leuven odkrył nowy potencjał terapeutyczny w leczeniu ciężkich postaci malarii. Naukowcy zidentyfikowali lek o nazwie ruxolitinib, który w testach laboratoryjnych wykazał…
Zespół badaczy z Instytutu Rega przy Katolickim Uniwersytecie w Leuven odkrył nowy potencjał terapeutyczny w leczeniu ciężkich postaci malarii. Naukowcy zidentyfikowali lek o nazwie ruxolitinib, który w testach laboratoryjnych wykazał…
KU Leuven: nowy trop w leczeniu najgroźniejszych form malarii
Zespół badaczy z Instytutu Rega przy Katolickim Uniwersytecie w Leuven odkrył nowy potencjał terapeutyczny w leczeniu ciężkich postaci malarii. Naukowcy zidentyfikowali lek o nazwie ruxolitinib, który w testach laboratoryjnych wykazał zdolność do przeciwdziałania groźnym skutkom ostrej malarii, takim jak gwałtowne reakcje zapalne i ciężka hipoglikemia. Testy przeprowadzono na myszach zakażonych malarią, u których pojawiły się objawy podobne do tych obserwowanych u ludzi.
aktualnosci.be
July 24, 2025 at 9:11 AM
KU Leuven: nowy trop w leczeniu najgroźniejszych form malarii
Zespół badaczy z Instytutu Rega przy Katolickim Uniwersytecie w Leuven odkrył nowy potencjał terapeutyczny w leczeniu ciężkich postaci malarii. Naukowcy zidentyfikowali lek o nazwie ruxolitinib, który w testach laboratoryjnych wykazał…
Zespół badaczy z Instytutu Rega przy Katolickim Uniwersytecie w Leuven odkrył nowy potencjał terapeutyczny w leczeniu ciężkich postaci malarii. Naukowcy zidentyfikowali lek o nazwie ruxolitinib, który w testach laboratoryjnych wykazał…
#INCY Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
https://www.stocktitan.net/news/INCY/incyte-announces-new-data-from-phase-3b-t-ru-e-ad4-trial-of-opzelura-d3x745ozwhz6.html
https://www.stocktitan.net/news/INCY/incyte-announces-new-data-from-phase-3b-t-ru-e-ad4-trial-of-opzelura-d3x745ozwhz6.html
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
These data will be presented during the Systemic and New Therapies for Atopic Dermatitis session on Sunday, October 26 at 10:55 a.m. AEDT at the 15th Georg Rajka International Symposium on Atopic Dermatitis, held from October 24– 26, 2025, in Melbourne. “The TRuE-AD4 data further reinforce the safety and efficacy profile of Opzelura and its ability to control...
www.stocktitan.net
October 25, 2025 at 11:55 PM
#INCY Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
https://www.stocktitan.net/news/INCY/incyte-announces-new-data-from-phase-3b-t-ru-e-ad4-trial-of-opzelura-d3x745ozwhz6.html
https://www.stocktitan.net/news/INCY/incyte-announces-new-data-from-phase-3b-t-ru-e-ad4-trial-of-opzelura-d3x745ozwhz6.html
pmc.ncbi.nlm.nih.gov/articles/PMC...
Some studies & #clinicaltrials have produced mixed results on the effectiveness of #ruxolitinib in treating #COVID complications.
www.novartis.com/news/media-r...
A 🔑 distinction lies in the nature of inflammation in acute & chronic disease. In severe #COVID,
Some studies & #clinicaltrials have produced mixed results on the effectiveness of #ruxolitinib in treating #COVID complications.
www.novartis.com/news/media-r...
A 🔑 distinction lies in the nature of inflammation in acute & chronic disease. In severe #COVID,
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
www.novartis.com
October 19, 2025 at 5:20 AM
pmc.ncbi.nlm.nih.gov/articles/PMC...
Some studies & #clinicaltrials have produced mixed results on the effectiveness of #ruxolitinib in treating #COVID complications.
www.novartis.com/news/media-r...
A 🔑 distinction lies in the nature of inflammation in acute & chronic disease. In severe #COVID,
Some studies & #clinicaltrials have produced mixed results on the effectiveness of #ruxolitinib in treating #COVID complications.
www.novartis.com/news/media-r...
A 🔑 distinction lies in the nature of inflammation in acute & chronic disease. In severe #COVID,
Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row - Medical Dialogues: Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row Medical Dialogues
Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row - Medical Dialogues
Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row Medical Dialogues
medicaldialogues.in
January 1, 2026 at 1:28 PM
Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row - Medical Dialogues: Delhi HC Bars Shilpa Medicare From Making, Selling Ruxolitinib Drugs in Patent Row Medical Dialogues
Ruxolitinib clears CRYAB p.Arg120Gly aggregates through the ubiquitin-proteasome system https://www.biorxiv.org/content/10.1101/2024.10.11.615348v1
Ruxolitinib clears CRYAB p.Arg120Gly aggregates through the ubiquitin-proteasome system https://www.biorxiv.org/content/10.1101/2024.10.11.615348v1
Protein accumulation is a hallmark of many neurodegenerative and muscular diseases. Desmin-related (
www.biorxiv.org
October 12, 2024 at 11:01 PM
Ruxolitinib clears CRYAB p.Arg120Gly aggregates through the ubiquitin-proteasome system https://www.biorxiv.org/content/10.1101/2024.10.11.615348v1
Ruxolitinib for refractory lung granulomatosis in two pediatric patients
https://pubmed.ncbi.nlm.nih.gov/40504025
https://pubmed.ncbi.nlm.nih.gov/40504025
June 13, 2025 at 10:04 AM
Ruxolitinib for refractory lung granulomatosis in two pediatric patients
https://pubmed.ncbi.nlm.nih.gov/40504025
https://pubmed.ncbi.nlm.nih.gov/40504025
Signal or noise? > Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of
Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
Dermatitis >> Comment below! #AI #industry40 #mhealth #IoT #healthtech
Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
Dermatitis >> Comment below! #AI #industry40 #mhealth #IoT #healthtech
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of
Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
Dermatitis
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) …
dlvr.it
October 26, 2025 at 1:36 AM
Signal or noise? > Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of
Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
Dermatitis >> Comment below! #AI #industry40 #mhealth #IoT #healthtech
Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
Dermatitis >> Comment below! #AI #industry40 #mhealth #IoT #healthtech
A question on #Ruxolitinib tabled by Michael Payne on 25-02-2025 has been answered by Karin Smyth. https://questions-statements.parliament.uk/written-questions/detail/2025-02-25/33692
March 3, 2025 at 1:01 PM
A question on #Ruxolitinib tabled by Michael Payne on 25-02-2025 has been answered by Karin Smyth. https://questions-statements.parliament.uk/written-questions/detail/2025-02-25/33692
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis @ash-hematology.bsky.social #ASH24 #hematology #oncology www.onclive.com/view/maic-po...
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
www.onclive.com
December 13, 2024 at 4:22 PM
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis @ash-hematology.bsky.social #ASH24 #hematology #oncology www.onclive.com/view/maic-po...
Janus Kinaz 1 (JAK1) ve JAK2 adlı inflamasyonla ilişkili iki sinyal proteinini inhibe eden ruxolitinib adlı ilaç, yalnızca JAK1 veya JAK2'yi inhibe eden diğer ilaçlardan daha üstünmüş.
March 8, 2024 at 6:55 PM
Janus Kinaz 1 (JAK1) ve JAK2 adlı inflamasyonla ilişkili iki sinyal proteinini inhibe eden ruxolitinib adlı ilaç, yalnızca JAK1 veya JAK2'yi inhibe eden diğer ilaçlardan daha üstünmüş.
Ruxolitinib is same situation for treatment of myelofibrosis ( blood cancer).
September 8, 2025 at 3:12 PM
Ruxolitinib is same situation for treatment of myelofibrosis ( blood cancer).
🚨 Latest Oncology update from #ASH2025!
✅ MaaT013 (Xervyteg®) shows durable survival benefit, achieving 54% 1-year OS in high-risk steroid + ruxolitinib-refractory aGvHD patients.
📌 Phase 3 ARES results now presented at #ASH2025. EMA review in progress with a decision expected mid-2026.
✅ MaaT013 (Xervyteg®) shows durable survival benefit, achieving 54% 1-year OS in high-risk steroid + ruxolitinib-refractory aGvHD patients.
📌 Phase 3 ARES results now presented at #ASH2025. EMA review in progress with a decision expected mid-2026.
December 10, 2025 at 1:00 PM
She Opze on my lura till I ruxolitinib cream 1.5%
October 16, 2024 at 11:12 PM
She Opze on my lura till I ruxolitinib cream 1.5%
yüksek riskli miyelofibrozisli yetişkin hastalar için bakım standardı ruxolitinib monoterapisine kıyasla, klinik iyileşmenin önemli bir göstergesi olan dalak büyümesini azaltmada iki kat daha etkili olmuş.
December 11, 2023 at 3:02 PM
yüksek riskli miyelofibrozisli yetişkin hastalar için bakım standardı ruxolitinib monoterapisine kıyasla, klinik iyileşmenin önemli bir göstergesi olan dalak büyümesini azaltmada iki kat daha etkili olmuş.